• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于相对效力的质子泵抑制剂的可互换使用。

Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency.

机构信息

Department of Medicine, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, Texas.

Department of Medicine, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, Texas.

出版信息

Clin Gastroenterol Hepatol. 2018 Jun;16(6):800-808.e7. doi: 10.1016/j.cgh.2017.09.033. Epub 2017 Sep 28.

DOI:10.1016/j.cgh.2017.09.033
PMID:28964908
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6913203/
Abstract

Although proton pump inhibitors (PPIs) are widely used, their relative potency and ideal dosing regimens remain unclear. We analyzed data from randomized clinical trials that performed pH testing in patients receiving solid-dose PPI formulations (omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole) for a minimum of 5 days. We used omeprazole equivalency and the surrogate biomarker, percentage time pH > 4 over a 24-hour period (pH4time), to compare PPI effectiveness for different PPIs given once, twice, or 3 times daily. We found that increasing strength of once-daily PPIs (9-64 mg omeprazole equivalents) increased pH4time linearly from approximately 10.0 to 15.6 hours; higher doses produced no further increase in pH4time. Increasing the frequency to twice-daily PPI increased pH4time linearly, from approximately 15.8 to 21.0 hours. Three-times daily PPIs performed similarly to twice-daily PPIs. The costs of PPIs varied greatly, but the cost variation was not directly related to potency. We conclude that PPIs can be used interchangeably based on potency. Using twice-daily PPIs is more effective in increasing efficacy increasing once-daily PPI dosage. Omeprazole and lansoprazole (30 mg) and 20 mg of esomeprazole rabeprazole are functionally equivalent.

摘要

虽然质子泵抑制剂(PPIs)被广泛应用,但它们的相对效力和理想的给药方案仍不清楚。我们分析了在接受固体制剂 PPI(奥美拉唑、埃索美拉唑、兰索拉唑、泮托拉唑、雷贝拉唑)治疗至少 5 天的患者中进行 pH 检测的随机临床试验数据。我们使用奥美拉唑等效物和替代生物标志物,即 24 小时内 pH > 4 的时间百分比(pH4time),来比较不同的 PPI 在每日一次、每日两次或每日三次给药时的效果。我们发现,增加每日一次 PPI(9-64mg 奥美拉唑等效物)的强度可使 pH4time 线性增加,从约 10.0 小时增加到 15.6 小时;更高的剂量不会进一步增加 pH4time。将频率增加到每日两次 PPI 可使 pH4time 线性增加,从约 15.8 小时增加到 21.0 小时。每日三次 PPI 的效果与每日两次 PPI 相似。PPIs 的成本差异很大,但成本变化与效力没有直接关系。我们的结论是,基于效力可以互换使用 PPI。增加每日两次 PPI 的使用频率比增加每日一次 PPI 的剂量更能提高疗效。奥美拉唑和兰索拉唑(30mg)以及埃索美拉唑和雷贝拉唑 20mg 在功能上等效。

相似文献

1
Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency.基于相对效力的质子泵抑制剂的可互换使用。
Clin Gastroenterol Hepatol. 2018 Jun;16(6):800-808.e7. doi: 10.1016/j.cgh.2017.09.033. Epub 2017 Sep 28.
2
Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.埃索美拉唑一日两次给药较奥美拉唑、雷贝拉唑或兰索拉唑能更有效地抑制 CYP2C19 快速代谢者的胃酸分泌。
Aliment Pharmacol Ther. 2013 Nov;38(9):1129-37. doi: 10.1111/apt.12492. Epub 2013 Sep 16.
3
Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI.质子泵抑制剂的相对效力、幽门螺杆菌治疗的治愈率以及双倍剂量 PPI 的意义。
Helicobacter. 2019 Feb;24(1):e12554. doi: 10.1111/hel.12554. Epub 2018 Nov 15.
4
Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.埃索美拉唑40毫克、雷贝拉唑20毫克、兰索拉唑30毫克和泮托拉唑40毫克对广泛代谢型胃食管反流病患者胃内pH值影响的比较。
Turk J Gastroenterol. 2016 Sep;27(5):408-414. doi: 10.5152/tjg.2016.15514.
5
Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.与奥美拉唑、雷尼替丁和安慰剂相比,新型质子泵抑制剂兰索拉唑、雷贝拉唑和泮托拉唑治疗胃食管反流病的愈合率和复发率:来自随机临床试验的证据。
Clin Ther. 2001 Jul;23(7):998-1017. doi: 10.1016/s0149-2918(01)80087-4.
6
Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.质子泵抑制剂的相对效价——对胃内pH值影响的比较
Eur J Clin Pharmacol. 2009 Jan;65(1):19-31. doi: 10.1007/s00228-008-0576-5. Epub 2008 Oct 17.
7
Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.在患有胃食管反流症状的患者中,40毫克埃索美拉唑比30毫克兰索拉唑、20毫克奥美拉唑、40毫克泮托拉唑和20毫克雷贝拉唑能更有效地控制胃内酸度。
Eur J Clin Pharmacol. 2004 Oct;60(8):531-9. doi: 10.1007/s00228-004-0804-6. Epub 2004 Sep 2.
8
Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.质子泵抑制药物奥美拉唑、埃索美拉唑、兰索拉唑、泮托拉唑和雷贝拉唑对人细胞色素P450活性的抑制作用比较。
Drug Metab Dispos. 2004 Aug;32(8):821-7. doi: 10.1124/dmd.32.8.821.
9
Combination drug therapy for gastroesophageal reflux disease.胃食管反流病的联合药物治疗
Ann Pharmacother. 2002 May;36(5):912-6. doi: 10.1345/aph.10247.
10
[New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].[新一代质子泵抑制剂:在消化性酸相关疾病治疗中的进展?]
Presse Med. 2004 Jun 19;33(11):746-54. doi: 10.1016/s0755-4982(04)98731-3.

引用本文的文献

1
Impact of Acid Suppressants on the Development of Infection and Possible Preventive Effects of Probiotic Formulations.抑酸剂对感染发生的影响及益生菌制剂的潜在预防作用
Infect Drug Resist. 2025 Aug 31;18:4593-4602. doi: 10.2147/IDR.S543864. eCollection 2025.
2
Diagnosis and Management of Gastroesophageal Reflux Disease: Current Insights.胃食管反流病的诊断与管理:当前见解
Clin Exp Gastroenterol. 2025 Jul 8;18:149-162. doi: 10.2147/CEG.S507237. eCollection 2025.
3
Do the new ACG treatment guidelines have implications for Canada?新的美国胃肠病学会(ACG)治疗指南对加拿大有影响吗?
J Can Assoc Gastroenterol. 2025 May 6;8(3):85-88. doi: 10.1093/jcag/gwaf008. eCollection 2025 Jun.
4
Vonoprazan and proton pump inhibitors: Which is superior for eradication?沃克和质子泵抑制剂:哪种在根除方面更具优势?
World J Gastroenterol. 2025 May 7;31(17):103156. doi: 10.3748/wjg.v31.i17.103156.
5
Oesophageal Dysmotility in a Patient with Charcot-Marie-Tooth Disease: Report and Literature Review.夏科-马里-图斯病患者的食管动力障碍:病例报告及文献综述
Eur J Case Rep Intern Med. 2025 Mar 17;12(4):005219. doi: 10.12890/2025_005219. eCollection 2025.
6
Effect of proton pump inhibitors on occlusion of lumen-apposing metal stents and rate of endoscopic necrosectomies: a Europe-wide multicenter cohort study.质子泵抑制剂对管腔贴附金属支架闭塞及内镜坏死组织切除术发生率的影响:一项欧洲范围内的多中心队列研究。
Endoscopy. 2025 Aug;57(8):829-838. doi: 10.1055/a-2569-7056. Epub 2025 Mar 31.
7
Esophageal Disorders in the Older Adult.老年人群中的食管疾病
Curr Treat Options Gastroenterol. 2025 Dec;23(1). doi: 10.1007/s11938-025-00468-6. Epub 2025 Feb 27.
8
Crises in Antimicrobial Stewardship: Misuse of Clarithromycin for Therapy.抗菌药物管理危机:克拉霉素治疗的不当使用
Pharmacoepidemiology. 2024 Mar;3(1):82-93. doi: 10.3390/pharma3010006. Epub 2024 Feb 20.
9
Management of Patients With Refractory Reflux-Like Symptoms Despite Proton Pump Inhibitor Therapy: Evidence-Based Consensus Statements.尽管接受质子泵抑制剂治疗仍有难治性反流样症状患者的管理:循证共识声明
Aliment Pharmacol Ther. 2025 Feb;61(4):636-650. doi: 10.1111/apt.18420. Epub 2024 Dec 30.
10
Efficacy of Vonoprazan 10 mg and 20 mg for Patients With Proton Pump Inhibitor-Refractory Functional Dyspepsia: A Double-Blinded, Randomized Study.10毫克和20毫克沃克索拉唑治疗质子泵抑制剂难治性功能性消化不良患者的疗效:一项双盲、随机研究。
JGH Open. 2024 Dec 20;8(12):e70082. doi: 10.1002/jgh3.70082. eCollection 2024 Dec.

本文引用的文献

1
Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression.质子泵抑制剂在酸相关性疾病中的有效与安全治疗——一份探讨抑酸益处及潜在危害的立场文件
BMC Med. 2016 Nov 9;14(1):179. doi: 10.1186/s12916-016-0718-z.
2
Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole.右兰索拉唑口腔崩解片制剂的药代动力学和药效学
Therap Adv Gastroenterol. 2016 Nov;9(6):759-769. doi: 10.1177/1756283X16670073. Epub 2016 Sep 29.
3
Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study.成人使用质子泵抑制剂的情况:一项丹麦全国性药物利用研究。
Therap Adv Gastroenterol. 2016 Sep;9(5):671-8. doi: 10.1177/1756283X16650156. Epub 2016 May 26.
4
Dexlansoprazole: delayed-release orally disintegrating tablets for the treatment of heartburn associated with non-erosive gastroesophageal reflux disease and the maintenance of erosive esophagitis.右兰索拉唑:用于治疗与非糜烂性胃食管反流病相关的烧心及维持糜烂性食管炎的口服崩解片。
Expert Rev Gastroenterol Hepatol. 2016 Oct;10(10):1083-1089. doi: 10.1080/17474124.2016.1230496.
5
Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).新型钾离子竞争性酸阻滞剂富马酸沃克索拉唑(TAK-438)的特性
Adv Ther. 2016 Jul;33(7):1140-57. doi: 10.1007/s12325-016-0345-2. Epub 2016 Jun 10.
6
Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.随机临床试验:新型钾离子竞争性酸阻滞剂沃克替尼与兰索拉唑治疗糜烂性食管炎的剂量范围研究。
Aliment Pharmacol Ther. 2015 Sep;42(6):685-95. doi: 10.1111/apt.13331. Epub 2015 Jul 22.
7
Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study.在健康成年男性受试者中,与埃索美拉唑 20mg 或雷贝拉唑 10mg 相比,沃诺拉赞 20mg 的抑酸作用——一项随机、开放标签交叉研究。
Aliment Pharmacol Ther. 2015 Sep;42(6):719-30. doi: 10.1111/apt.13325. Epub 2015 Jul 21.
8
Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.随机临床试验:新型钾离子竞争性酸阻滞剂TAK-438(沃克拉唑)在健康男性受试者中重复给药的安全性、耐受性、药代动力学和药效学
Aliment Pharmacol Ther. 2015 Apr;41(7):636-48. doi: 10.1111/apt.13121. Epub 2015 Feb 23.
9
Long-term effect on symptoms and quality of life of maintenance therapy with esomeprazole 20 mg daily: a post hoc analysis of the LOTUS trial.每日服用20毫克埃索美拉唑维持治疗对症状及生活质量的长期影响:LOTUS试验的事后分析
Curr Med Res Opin. 2015 Jan;31(1):65-73. doi: 10.1185/03007995.2014.980500. Epub 2014 Oct 31.
10
National use of proton pump inhibitors from 2007 to 2011.2007年至2011年质子泵抑制剂的全国使用情况。
JAMA Intern Med. 2014 Nov;174(11):1856-8. doi: 10.1001/jamainternmed.2014.2900.